Figure 131

Despite differing structures, both cyclosporine and tacrolimus bind to intracellular receptors in T cells, forming a combination that then inhibits calcineurin-dependent pathways of cell activation. Although slight differences exist in side-effect profiles between the two drugs, their overall impact is remarkably similar. In many cases, dose reduction may ameliorate the toxic effect; however, the benefit of dose reduction must be weighed against increasing the risk of acute rejection in each patient. CyA-cyclosporine; FK-tacrolimus.

0 0

Post a comment